Sanofi (NASDAQ:SNY) Cut to “Buy” at Wall Street Zen

Sanofi (NASDAQ:SNY) was downgraded by research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

Other research analysts also recently issued research reports about the stock. Jefferies Financial Group reissued a “buy” rating on shares of Sanofi in a research report on Monday, October 27th. TD Cowen reiterated a “hold” rating on shares of Sanofi in a research note on Tuesday, December 30th. Barclays downgraded Sanofi from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, January 6th. UBS Group reaffirmed a “neutral” rating on shares of Sanofi in a research report on Friday, January 16th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Sanofi in a report on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $62.67.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $46.76 on Friday. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.09 and a quick ratio of 0.29. The business has a 50-day moving average of $47.55 and a 200-day moving average of $48.55. The stock has a market capitalization of $114.05 billion, a price-to-earnings ratio of 12.99, a PEG ratio of 1.23 and a beta of 0.45. Sanofi has a fifty-two week low of $44.62 and a fifty-two week high of $60.12.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Morgan Stanley grew its position in Sanofi by 20.4% during the fourth quarter. Morgan Stanley now owns 9,102,196 shares of the company’s stock worth $441,093,000 after buying an additional 1,540,271 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Sanofi by 5.4% during the 4th quarter. Invesco Ltd. now owns 6,110,874 shares of the company’s stock worth $296,133,000 after purchasing an additional 313,327 shares in the last quarter. Raymond James Financial Inc. increased its position in shares of Sanofi by 81.3% in the second quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock worth $284,058,000 after purchasing an additional 2,635,867 shares during the period. Franklin Resources Inc. increased its position in shares of Sanofi by 29.7% in the fourth quarter. Franklin Resources Inc. now owns 5,100,097 shares of the company’s stock worth $247,151,000 after purchasing an additional 1,168,339 shares during the period. Finally, Mondrian Investment Partners LTD raised its stake in Sanofi by 23.5% in the fourth quarter. Mondrian Investment Partners LTD now owns 4,495,348 shares of the company’s stock valued at $217,845,000 after purchasing an additional 856,742 shares in the last quarter. 14.03% of the stock is owned by institutional investors.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.